About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

High Doses of Candesartan Cilexetil on the Reduction of Proteinuria

NCT00242346·26 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Informed consent
Stable hypertension defined as no new antihypertensive medication started within 6 weeks of Visit 1
Minimum 6-month history of hypertension and primary glomerular disease
Hypertensive nephrosclerosis
Diabetic nephropathy with stable proteinuria as defined by ≥ 1g/24 hours on more than one occasion within 6 months prior to Visit 1

You may not be if

Persistent hypertension
New anti-hypertensive medications started within 6 weeks of Visit 1
Significant cardiac disease or Liver disease
Females of childbearing potential without reliable contraception
Pregnant women and women who are breast-feeding

The record

StatusCompleted

PhasePhase 3

Taking part270

StartedApr 2003

UpdatedDec 19, 2007

Conditions

Where26

Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Kelowna, British Columbia, Canada

Clareo Health | High Doses of Candesartan Cilexetil on the Reduction of Proteinuria